397 related articles for article (PubMed ID: 23744810)
21. The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation.
Hakim GD; Akarsu M; Karademir S; Unek T; Astarcıoğlu İ
Turk J Gastroenterol; 2014 Dec; 25(6):685-9. PubMed ID: 25599782
[TBL] [Abstract][Full Text] [Related]
22. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
[TBL] [Abstract][Full Text] [Related]
23. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
24. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.
Fung J; Chan SC; Cheung C; Yuen MF; Chok KS; Sharr W; Chan AC; Cheung TT; Seto WK; Fan ST; Lai CL; Lo CM
Am J Gastroenterol; 2013 Jun; 108(6):942-8. PubMed ID: 23629601
[TBL] [Abstract][Full Text] [Related]
25. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
[TBL] [Abstract][Full Text] [Related]
26. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
Choudhary NS; Saraf N; Saigal S; Mohanka R; Rastogi A; Goja S; Menon PB; Soin AS
Transpl Infect Dis; 2015 Jun; 17(3):329-33. PubMed ID: 25682715
[TBL] [Abstract][Full Text] [Related]
27. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
[TBL] [Abstract][Full Text] [Related]
28. Prevention of hepatitis B virus reinfection in liver transplant recipients.
Roche B; Samuel D
Intervirology; 2014; 57(3-4):196-201. PubMed ID: 25034488
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report.
Shan C; Yin GQ; Wu P
J Med Case Rep; 2014 Aug; 8():281. PubMed ID: 25146249
[TBL] [Abstract][Full Text] [Related]
30. The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation.
Tanaka T; Benmousa A; Marquez M; Therapondos G; Renner EL; Lilly LB
Clin Transplant; 2012; 26(5):E561-9. PubMed ID: 23061767
[TBL] [Abstract][Full Text] [Related]
31. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B.
Lo AO; Wong VW; Wong GL; Tse YK; Chan HY; Chan HL
Aliment Pharmacol Ther; 2015 Jun; 41(11):1190-9. PubMed ID: 25825194
[TBL] [Abstract][Full Text] [Related]
33. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
Patterson SJ; Angus PW
Curr Opin Organ Transplant; 2009 Jun; 14(3):225-30. PubMed ID: 19373086
[TBL] [Abstract][Full Text] [Related]
34. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
Yang Y; Zhang Q; Cai CJ; Lu MQ; Li X; Jiang N; Jiang H; Xu C; Li H; Wang GS; Yi SH; Zhang J; Zhang JF; Yi HM; Zhang YC; Chen GH
Chin Med J (Engl); 2007 Aug; 120(16):1400-3. PubMed ID: 17825167
[TBL] [Abstract][Full Text] [Related]
35. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
[TBL] [Abstract][Full Text] [Related]
36. The option of liver transplantation for hepatitis B: where are we?
Samuel D
Dig Liver Dis; 2009 May; 41 Suppl 2():S185-9. PubMed ID: 19482255
[TBL] [Abstract][Full Text] [Related]
37. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation.
Na GH; Kim DG; Han JH; Kim EY; Lee SH; Hong TH; You YK; Choi JY
J Gastroenterol Hepatol; 2014 Jan; 29(1):151-6. PubMed ID: 24117684
[TBL] [Abstract][Full Text] [Related]
38. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade.
Neff GW; O'brien CB; Nery J; Shire N; Montalbano M; Ruiz P; Nery C; Safdar K; De Medina M; Tzakis AG; Schiff ER; Madariaga J
Liver Transpl; 2004 Nov; 10(11):1372-8. PubMed ID: 15497163
[TBL] [Abstract][Full Text] [Related]
39. Management of hepatitis B in liver transplant recipients.
Coffin CS; Terrault NA
J Viral Hepat; 2007 Nov; 14 Suppl 1():37-44. PubMed ID: 17958641
[TBL] [Abstract][Full Text] [Related]
40. Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection.
Perrakis A; Förtsch T; Del Medico A; Croner RS; Vassos N; Yedibela S; Lohmüller C; Zopf S; Hohenberger W; Müller V
Transplant Proc; 2013 Jun; 45(5):1953-6. PubMed ID: 23769081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
